triiodothyronine has been researched along with Melanoma in 8 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "1) by imidazole was determined in cultured B16/C3 melanoma cells." | 7.67 | Retinoic acid blockade of imidazole-induced tyrosinase expression in B16 melanoma cultures: similar effects of the active retinoid and triiodothyronine. ( Kline, EL; Smith, TJ; Warren, JT, 1989) |
| "Investigations with mouse melanoma B16/C3 cell cultures have suggested that imidazole or a derivative thereof can facilitate expression of the tyrosinase (EC 1." | 7.67 | Triiodothyronine repression of imidazole-induced tyrosinase expression in B16 melanoma cells. ( Carland, K; Kline, EL; Smith, TJ, 1986) |
| "3,3',5-L-triiodothyronine (T3) can inhibit tyrosinase activity in B16/C3 melanoma cells in culture and block the induction of that enzyme by imidazole (Endocrinol." | 7.67 | 3,3',5-L-triiodothyronine but not L-thyroxine can block the induction of tyrosinase by imidazole in cultured B16 melanoma cells. ( Kline, EL; Smith, TJ, 1988) |
| "1) by imidazole was determined in cultured B16/C3 melanoma cells." | 3.67 | Retinoic acid blockade of imidazole-induced tyrosinase expression in B16 melanoma cultures: similar effects of the active retinoid and triiodothyronine. ( Kline, EL; Smith, TJ; Warren, JT, 1989) |
| "Investigations with mouse melanoma B16/C3 cell cultures have suggested that imidazole or a derivative thereof can facilitate expression of the tyrosinase (EC 1." | 3.67 | Triiodothyronine repression of imidazole-induced tyrosinase expression in B16 melanoma cells. ( Carland, K; Kline, EL; Smith, TJ, 1986) |
| "3,3',5-L-triiodothyronine (T3) can inhibit tyrosinase activity in B16/C3 melanoma cells in culture and block the induction of that enzyme by imidazole (Endocrinol." | 3.67 | 3,3',5-L-triiodothyronine but not L-thyroxine can block the induction of tyrosinase by imidazole in cultured B16 melanoma cells. ( Kline, EL; Smith, TJ, 1988) |
| "Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs)." | 1.51 | Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. ( Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A, 2019) |
| " Levothyroxine dosing required doubling in three patients with a known history of hypothyroidism." | 1.46 | Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. ( Bornschlegl, S; Delivanis, DA; Dietz, AB; Gustafson, MP; Kottschade, L; Merten, MM; Ryder, M; Withers, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamauchi, I | 2 |
| Sakane, Y | 1 |
| Fukuda, Y | 1 |
| Fujii, T | 2 |
| Taura, D | 2 |
| Hirata, M | 1 |
| Hirota, K | 1 |
| Ueda, Y | 1 |
| Kanai, Y | 1 |
| Yamashita, Y | 1 |
| Kondo, E | 1 |
| Sone, M | 2 |
| Yasoda, A | 2 |
| Inagaki, N | 2 |
| Delivanis, DA | 1 |
| Gustafson, MP | 1 |
| Bornschlegl, S | 1 |
| Merten, MM | 1 |
| Kottschade, L | 1 |
| Withers, S | 1 |
| Dietz, AB | 1 |
| Ryder, M | 1 |
| Ansorge, C | 1 |
| Seufert, J | 1 |
| Meiss, F | 1 |
| von Bubnoff, D | 1 |
| Matsumoto, S | 1 |
| Sakamori, Y | 1 |
| Kim, YH | 1 |
| Nomura, M | 1 |
| Otsuka, A | 1 |
| Yamasaki, T | 1 |
| Saito, R | 1 |
| Kitamura, M | 1 |
| Kitawaki, T | 1 |
| Hishizawa, M | 1 |
| Kawaguchi-Sakita, N | 1 |
| Tanaka, R | 1 |
| Fujisawa, Y | 1 |
| Maruyama, H | 1 |
| Nakamura, Y | 1 |
| Yoshino, K | 1 |
| Ohtsuka, M | 1 |
| Fujimoto, M | 1 |
| Smith, TJ | 3 |
| Warren, JT | 1 |
| Kline, EL | 3 |
| Carland, K | 1 |
8 other studies available for triiodothyronine and Melanoma
| Article | Year |
|---|---|
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lung Neoplasm | 2017 |
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autoantibo | 2017 |
Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
Topics: Adult; Antineoplastic Agents, Immunological; Autoimmune Hypophysitis; Humans; Hydrocortisone; Hypopi | 2018 |
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxygluco | 2019 |
Nivolumab-induced thyroid dysfunction.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Female; Hormone Replacement | 2016 |
Retinoic acid blockade of imidazole-induced tyrosinase expression in B16 melanoma cultures: similar effects of the active retinoid and triiodothyronine.
Topics: Animals; Catechol Oxidase; Cell Line; Enzyme Induction; Imidazoles; Melanoma; Mice; Monophenol Monoo | 1989 |
Triiodothyronine repression of imidazole-induced tyrosinase expression in B16 melanoma cells.
Topics: Animals; Catechol Oxidase; Cell Division; Cell Line; Dactinomycin; Dose-Response Relationship, Drug; | 1986 |
3,3',5-L-triiodothyronine but not L-thyroxine can block the induction of tyrosinase by imidazole in cultured B16 melanoma cells.
Topics: Animals; Catechol Oxidase; Cells, Cultured; Enzyme Induction; Imidazoles; Melanoma; Mice; Monophenol | 1988 |